Gic

GIC Pte. Ltd. is a sovereign wealth fund wholly owned by the Government of Singapore, established in 1981 to manage the country’s foreign reserves. The firm focuses on securing Singapore's financial future by investing across a diverse range of asset classes in both public and private markets. Its investment strategy includes public and private equity, with particular emphasis on health care, financial services, natural resources, real estate, and fixed income, as well as alternative markets such as foreign exchange and commodities. GIC also engages in venture capital, providing seed capital to start-ups and growth companies. The organization operates through subsidiaries that specialize in various investment categories and maintains a global presence with offices in key financial centers around the world. GIC aims to achieve sustainable long-term returns above global inflation, thereby fulfilling its responsibility to preserve and enhance Singapore's financial reserves for future generations.

Ethel Chen

SVP, Venture Capital and Technology Investing

Chow Kiat Lim

CEO and Founder

Henry Ormond

Head of Private Equity

Sam Rosen

Investor

Bryan Yeo

Chief Investment Officer, Public Equities

Past deals in Rotterdam

Harbour BioMed

Series B in 2020
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

Harbour BioMed

Series B in 2018
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.